Good morning, HealthTech insiders. A treatment already used by adults with obstructive hypertrophic cardiomyopathy can now be prescribed to eligible children. On Wednesday, the FDA expanded the Camzyos label after a small trial showed a substantial reduction in the pressure gradient that obstructs blood leaving the heart. It is a meaningful new option for families, even as longer follow-up is needed to establish what it changes over a lifetime.
Two other developments could reshape how care is delivered and paid for. ARPA-H opened a program seeking faster, more adaptable clinical trials, while new Medicare add-on payments took effect for eligible inpatient use of sepsis and imaging AI. One is an approved treatment, one is a research program seeking builders, and one is a payment pathway hospitals can use now. Their next tests are long-term outcomes, working trial infrastructure, and value in everyday care.
In today's Signal:
Camzyos reaches pediatric patients: The FDA expanded its indication to patients weighing at least 30 kg with symptomatic obstructive hypertrophic cardiomyopathy. In the 44-person SCOUT-HCM trial, treatment reduced a measure of cardiac obstruction at 28 weeks.
ARPA-H opens SURPASS: The agency is seeking teams to develop clinical-trial designs that combine predictive models, shared controls, ongoing analysis, and more efficient operations. Applications are still ahead.
Medicare’s clinical AI payments begin: From October 1, qualifying inpatient use of Bayesian Health’s sepsis device and Aidoc’s CARE Body CT Multi-Triage can receive New Technology Add-on Payments, subject to case-specific rules.
What we’re watching: Whether pediatric follow-up supports sustained benefit, SURPASS attracts credible development teams, and hospitals can document both clinical value and payment eligibility.
In partnership with
The Best Marketing Angle You’ve Never Tried
Everyone wants a marketing hack that makes growing their business easier.
But according to business guru @MarketingMax (9 figures in attributable revenue delivered to clients), one of the best no-cost marketing hacks is finding the one angle that makes people foam at the mouth wanting what you sell.
Lucky for you @MarketingMax put together a quick 2-page Google Doc breaking down how to find yours in 10 minutes, with 20+ real examples you can steal from.
LATEST DEVELOPMENTS
PEDIATRIC CARDIOLOGY & FDA APPROVAL
1. FDA Expands Camzyos Approval to Children With Obstructive HCM
The FDA expanded Bristol Myers Squibb’s Camzyos (mavacamten) indication on September 30 to include pediatric patients weighing at least 30 kg with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The approved use is to improve functional capacity and symptoms.
The details:
The trial: SCOUT-HCM randomized 44 adolescents aged 12 to under 18: 23 received Camzyos and 21 received placebo. At week 28, the placebo-adjusted reduction in provoked left ventricular outflow tract gradient was 48.0 mm Hg, the trial’s primary endpoint.
The boundary: The study did not establish that treatment prevents septal surgery or improves lifelong outcomes. Other gradient and heart-structure measures were reported, but the secondary comparisons were descriptive.
The safeguard: Camzyos can cause heart failure through reduced cardiac pumping function. Prescribers must follow its risk-management requirements and monitor left ventricular ejection fraction.
The Signal: Pediatric cardiologists now have an approved, disease-specific medicine to consider alongside established care. The question for longer follow-up is whether lowering obstruction in adolescence also changes symptoms, later interventions, and safety over time.
CLINICAL TRIALS & FEDERAL RESEARCH
2. ARPA-H Opens SURPASS Program for More Adaptive Clinical Trials
On September 30, HHS and ARPA-H announced SURPASS, a funding program seeking new ways to design and run clinical trials. Its proposed approach combines predictive modeling, shared trial infrastructure, common control groups, ongoing analysis, and operational automation. The program is soliciting proposals; it has not yet demonstrated a faster national trial system.
The details:
Trial design: ARPA-H wants teams to test how digital twins and other predictive models could improve trial planning before patients enroll.
Analysis and operations: The program also seeks methods for analyzing accumulating data and adapting trials while preserving rigorous evidence, plus tools to speed startup and data preparation.
The next milestone: An informational webinar is set for October 15. Solution summaries are due November 30, with full proposals due January 22, 2027.
The Signal: SURPASS puts federal attention on the infrastructure behind slow, costly trials. Its significance will depend on what funded teams build, whether their methods withstand regulatory scrutiny, and whether they shorten development without weakening the evidence clinicians need.
MEDICARE PAYMENT & CLINICAL AI
3. Medicare Add-on Payments Begin for Eligible Sepsis and Imaging AI Use
Bayesian Health’s AI-powered sepsis monitoring platform. Image: Bayesian Health.
New Technology Add-on Payment eligibility began October 1 under Medicare’s fiscal 2027 inpatient payment rules for qualifying use of Bayesian Health’s sepsis flagging device and Aidoc’s CARE Body CT Multi-Triage. NTAP can supplement an eligible hospital payment; it is not an automatic payment for every alert, scan, or admission.
The details:
Bayesian Health: The company says qualifying discharges may receive up to $61.84 above the applicable Medicare inpatient payment. Approximately 739 diagnosis-related groups are eligible, but inclusion in one of those groups does not by itself make a discharge payable.
Aidoc: Qualifying Medicare fee-for-service inpatient use of its FDA-cleared CT triage technology is eligible for an add-on payment. Hospitals must assess the applicable requirements for each case.
The financial test: These payments may offset adoption costs. Their actual value to a hospital depends on eligible case volume, documentation, payment rules, and the cost of implementing the technology.
The Signal: CMS has given two clinical AI products a more concrete inpatient payment path. Health systems still need to show that the tools improve care and fit their workflows; NTAP eligibility alone does not establish a positive return.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Camzyos follow-up: How the pediatric evidence develops beyond 28 weeks, particularly for sustained symptoms, cardiac function, and subsequent need for invasive treatment.
SURPASS proposals: Which teams can pair adaptive statistics with practical trial operations, and how they plan to generate evidence regulators can evaluate.
NTAP in practice: How many inpatient cases meet the payment requirements, what hospitals receive, and whether measured clinical benefits justify deployment costs.
💰 FOLLOW THE MONEY
The deals:
Up to $61.84: Bayesian Health’s stated maximum add-on payment per eligible Medicare inpatient discharge. That is a payment ceiling for qualifying cases, not a forecast of hospital revenue.
A new purchasing consideration: Aidoc’s NTAP eligibility gives hospitals another factor to include when assessing its CT triage product. Individual cases still have to qualify.
A funding opportunity, not a completed investment: ARPA-H has opened the SURPASS solicitation. Its awardees and the performance of their proposed systems remain to be determined.
The pattern: Payment eligibility can help a hospital make an adoption case, while federal funding can help teams develop trial infrastructure. Neither substitutes for evidence that a product works in routine use or that its benefits exceed its costs.
📆 UPCOMING HEALTHTECH EVENTS
Global Health Exhibition 2026: October 26–29 | Riyadh, Saudi Arabia. A gathering focused on healthcare systems, technology, and investment.
HLTH USA 2026: November 15–18 | Las Vegas, NV. Healthcare leaders, payers, founders, and investors meet to discuss innovation and deployment.
RSNA 2026: November 29–December 3 | Chicago, IL. Radiology’s annual meeting, including imaging research and AI applications.
🛠️ Trending HealthTech AI Tools
Nabla Clinical AI Layer: Ambient documentation, dictation, and coding suggestions designed to fit clinical and EHR workflows; clinicians retain responsibility for final coding decisions.
QuantHealth clinical-trial simulation platform: Models potential trial outcomes to help development teams examine study-design choices before enrollment.
Cortechs.ai NeuroQuant PET: Automates regional amyloid PET quantification and Centiloid scoring. Its tau reporting is designated research use only, not FDA-cleared clinical functionality.
🛠️ Trending HealthTech AI Startups
Atman Health: Selected for ARPA-H’s ADVOCATE program to develop a voice-first, patient-facing cardiovascular AI agent. The program is developing and evaluating these systems; it is not an announcement of routine clinical deployment.
Orbis Medicines: Uses AI-enabled design and experimental chemistry to develop oral macrocycles. Its recently announced Novo Nordisk collaboration focuses on cardiometabolic disease.
RespondHealth: Builds governed clinical-data and real-world-evidence tools for research and treatment questions. It is not an emergency-department computer-vision or nurse-dispatch startup.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
What Camzyos’ Pediatric Approval Means for Obstructive HCM Care
What SCOUT-HCM established, why cardiac monitoring matters, and which long-term clinical and economic questions remain unanswered.Building the Next Trial Platform: What ARPA-H’s SURPASS Solicitation Proposes
A look at the proposed design, analysis, and operations tools—and the evidence their eventual builders will need to produce.When Medicare Helps Pay for Clinical AI: What NTAP Changes
How eligibility for Bayesian Health and Aidoc works, and why qualifying volume, implementation costs, and outcomes determine its value to hospitals.
Which result would most strengthen the case for adopting clinical AI in hospitals?
That's it for today!
A child with obstructive HCM now has another treatment option. Trial designers have a new federal call to build better ways of testing treatments. And hospitals using two clinical AI products have a route to supplemental Medicare payment for qualifying inpatient cases.
Those are three different kinds of progress. The next evidence matters as much as the milestone: Can Camzyos’ benefits hold up over years? Can SURPASS teams make adaptive trials work under rigorous review? And can hospitals show that reimbursed AI improves care in the patients who receive it?
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal